In humans, retrospective cohort studies have found people taking GLP-1RAs are less likely to develop alcohol use disorder (AUD) 16 and less likely to be hospitalized for acute alcohol intoxication 17
In mice with DSS-induced colitis, treatment with 3.6 M Amuc_1409* per day induced body weight gain, increased colon length and lowered the histopathological score in the distal colon
10.1111/j.1464-5491.2010.03010.x 70
External resources STEP 1 Trial: Semaglutide in Adults with Overweight or Obesity (NEJM) SURMOUNT-1 Trial: Tirzepatide for Treatment of Obesity (NEJM) NIH BMI Calculator (National Heart, Lung, and Blood Institute) For researchers serious about navigating GLP-1 eligibility and optimizing their treatment protocols, SeekPeptides offers the most comprehensive resource available
GC67918 MPO-IN-1 GC36650 MPO-IN-28 MPO-IN-28 (Compound 28) is a myeloperoxidase (MPO) inhibitor with an IC50 of 44 nM
When youre eating less, it becomes much easier to miss key nutrients without realizing it